LyGenesis closes $4 Million Convertible Debt Financing to begin Clinical Development of Liver Regeneration Technology
LyGenesis, Inc., a biotechnology company focused on organ regeneration, announced today that they have completed a total of $4 million in private financing of convertible notes from Juvenescence, Ltd. and Longevity Vision Fund. Their technology uses lymph nodes as bioreactors to regrow functioning organs within a patient’s own body. This financing will enable LyGenesis’s lead program in liver regeneration to transition into clinical development, beginning with a Phase 2a clinical trial for patients with end stage liver disease in 2020.
“We have advanced our liver regeneration program through preclinical trials and this financing will help us to rapidly transition into a clinical-stage biotechnology company,” said
“We are thrilled to continue our financial support of LyGenesis as they transition into clinical development,” said
ABOUT LYGENESIS, INC.
LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patient’s lymph nodes to be used as bioreactors to regrow functioning ectopic organs. LyGenesis’s lead allogeneic cell therapy program is focused on liver regeneration for patients with end-stage liver disease. Its drug development pipeline includes thymus, pancreas, and kidney regeneration. Privately held, LyGenesis is headquartered in Pittsburgh, Pennsylvania. To learn more, please visit lygenesis.com.
ABOUT JUVENESCENCE LTD.
Juvenescence Limited is a life sciences company developing therapies to modify aging and increase healthy human longevity. It was founded by
ABOUT LONGEVITY VISION FUND
Longevity Vision Fund is a $100M life extension-focused investment fund dedicated to making longevity affordable and accessible to all. Founded by Sergey Young, the fund accelerates breakthroughs in longevity by investing in start-ups and companies that develop technologies, products, and services that extend human lifespans and overcome the negative effects of aging. The Fund provides funding to biotech and life extension-focused companies developing early diagnostics, AI in healthcare, and therapies addressing age-related diseases. To learn more, please visit lvf.vc.
Link to the Press Release found here.